Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Various radioisotopes conjugated to pyrosphosphate analogues have been developed for systemic metabolic radiotherapy. Samarium-153-EDTMP is a 1:1 complex of radioactive Samarium-153 and a Tetraphosphonate [ethylenediamine-tetramethylene phosphonic acid (EDTMP)]. Samarium Sm-153-EDTMP has a high affinity for skeletal tissue and concentrates by chemiabsorption in areas of enhanced metabolic activity, where it associates with the hydroxyappetite crystal. Samarium-153 Lexidronam [Quadramet (R)] has been approved for routine use by the FDA. This agent offers several advantages over other agents used for palliating bone pain. Due to its half-life of 46 hours and its beta emissions, a high dose rate can be delivered to regions adjacent to enhanced osteoblastic activity over a short period of time with little residual long term activity being left in the bone marrow. This paper summarizes both animal studies and clinical studies performed with this agent. Special emphasis will be given to the pivotal Phase-III clinical studies and subsequent studies performed since its approval by the FDA. Special considerations regarding appropriate selection of patients, preperation, follow-up of patients and adjustments to the usual recommended dose [1 mCi/kg (35 Mbq/kg)] will be discussed. Current and future treatment options utilizing Sm 153-EDTMP with other pharmaceuticals appear promising and will substantially extend its use into new areas. In addition, because it also emits a 103 keV gamma ray which makes it suitable for imaging and assessment of biodistribution, dosimetric applications are possible in the future.

Original languageEnglish
Pages (from-to)91-99
Number of pages9
JournalQuarterly Journal of Nuclear Medicine
Volume45
Issue number1
StatePublished - Jul 9 2001

Fingerprint

ethylenediamine
Samarium
Radiotherapy
Neoplasm Metastasis
Bone and Bones
Social Adjustment
Gamma Rays
Therapeutics
Radioisotopes
Patient Selection
Half-Life
Bone Marrow
Pain
phosphonic acid

Keywords

  • Bone neoplasms
  • Bone neoplasms, secondary
  • Pain
  • Palliative care
  • Radiotherapy
  • Samarium

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{85d06e0e0097453888ecf82264d3ab39,
title = "Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis",
abstract = "Various radioisotopes conjugated to pyrosphosphate analogues have been developed for systemic metabolic radiotherapy. Samarium-153-EDTMP is a 1:1 complex of radioactive Samarium-153 and a Tetraphosphonate [ethylenediamine-tetramethylene phosphonic acid (EDTMP)]. Samarium Sm-153-EDTMP has a high affinity for skeletal tissue and concentrates by chemiabsorption in areas of enhanced metabolic activity, where it associates with the hydroxyappetite crystal. Samarium-153 Lexidronam [Quadramet (R)] has been approved for routine use by the FDA. This agent offers several advantages over other agents used for palliating bone pain. Due to its half-life of 46 hours and its beta emissions, a high dose rate can be delivered to regions adjacent to enhanced osteoblastic activity over a short period of time with little residual long term activity being left in the bone marrow. This paper summarizes both animal studies and clinical studies performed with this agent. Special emphasis will be given to the pivotal Phase-III clinical studies and subsequent studies performed since its approval by the FDA. Special considerations regarding appropriate selection of patients, preperation, follow-up of patients and adjustments to the usual recommended dose [1 mCi/kg (35 Mbq/kg)] will be discussed. Current and future treatment options utilizing Sm 153-EDTMP with other pharmaceuticals appear promising and will substantially extend its use into new areas. In addition, because it also emits a 103 keV gamma ray which makes it suitable for imaging and assessment of biodistribution, dosimetric applications are possible in the future.",
keywords = "Bone neoplasms, Bone neoplasms, secondary, Pain, Palliative care, Radiotherapy, Samarium",
author = "Serafini, {Aldo N}",
year = "2001",
month = "7",
day = "9",
language = "English",
volume = "45",
pages = "91--99",
journal = "Quarterly Journal of Nuclear Medicine and Molecular Imaging",
issn = "1824-4785",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis

AU - Serafini, Aldo N

PY - 2001/7/9

Y1 - 2001/7/9

N2 - Various radioisotopes conjugated to pyrosphosphate analogues have been developed for systemic metabolic radiotherapy. Samarium-153-EDTMP is a 1:1 complex of radioactive Samarium-153 and a Tetraphosphonate [ethylenediamine-tetramethylene phosphonic acid (EDTMP)]. Samarium Sm-153-EDTMP has a high affinity for skeletal tissue and concentrates by chemiabsorption in areas of enhanced metabolic activity, where it associates with the hydroxyappetite crystal. Samarium-153 Lexidronam [Quadramet (R)] has been approved for routine use by the FDA. This agent offers several advantages over other agents used for palliating bone pain. Due to its half-life of 46 hours and its beta emissions, a high dose rate can be delivered to regions adjacent to enhanced osteoblastic activity over a short period of time with little residual long term activity being left in the bone marrow. This paper summarizes both animal studies and clinical studies performed with this agent. Special emphasis will be given to the pivotal Phase-III clinical studies and subsequent studies performed since its approval by the FDA. Special considerations regarding appropriate selection of patients, preperation, follow-up of patients and adjustments to the usual recommended dose [1 mCi/kg (35 Mbq/kg)] will be discussed. Current and future treatment options utilizing Sm 153-EDTMP with other pharmaceuticals appear promising and will substantially extend its use into new areas. In addition, because it also emits a 103 keV gamma ray which makes it suitable for imaging and assessment of biodistribution, dosimetric applications are possible in the future.

AB - Various radioisotopes conjugated to pyrosphosphate analogues have been developed for systemic metabolic radiotherapy. Samarium-153-EDTMP is a 1:1 complex of radioactive Samarium-153 and a Tetraphosphonate [ethylenediamine-tetramethylene phosphonic acid (EDTMP)]. Samarium Sm-153-EDTMP has a high affinity for skeletal tissue and concentrates by chemiabsorption in areas of enhanced metabolic activity, where it associates with the hydroxyappetite crystal. Samarium-153 Lexidronam [Quadramet (R)] has been approved for routine use by the FDA. This agent offers several advantages over other agents used for palliating bone pain. Due to its half-life of 46 hours and its beta emissions, a high dose rate can be delivered to regions adjacent to enhanced osteoblastic activity over a short period of time with little residual long term activity being left in the bone marrow. This paper summarizes both animal studies and clinical studies performed with this agent. Special emphasis will be given to the pivotal Phase-III clinical studies and subsequent studies performed since its approval by the FDA. Special considerations regarding appropriate selection of patients, preperation, follow-up of patients and adjustments to the usual recommended dose [1 mCi/kg (35 Mbq/kg)] will be discussed. Current and future treatment options utilizing Sm 153-EDTMP with other pharmaceuticals appear promising and will substantially extend its use into new areas. In addition, because it also emits a 103 keV gamma ray which makes it suitable for imaging and assessment of biodistribution, dosimetric applications are possible in the future.

KW - Bone neoplasms

KW - Bone neoplasms, secondary

KW - Pain

KW - Palliative care

KW - Radiotherapy

KW - Samarium

UR - http://www.scopus.com/inward/record.url?scp=0034960433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034960433&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 91

EP - 99

JO - Quarterly Journal of Nuclear Medicine and Molecular Imaging

JF - Quarterly Journal of Nuclear Medicine and Molecular Imaging

SN - 1824-4785

IS - 1

ER -